


**3-Year Follow-up of Chemotherapy  
Following Radium-223 Dichloride in  
Castration-Resistant Prostate Cancer  
Patients With Symptomatic Bone  
Metastases From ALSYMPCA**

**Presented by: Neal Shore, MD**

***Carolina Urologic Research Center, Myrtle Beach, SC, USA***

# Patients

- Of 921 ALSYMPCA patients, 206 (22%) received chemotherapy post-study drug (radium-223: n = 142; placebo: n = 64)
- Docetaxel was the most common chemotherapy; 70% post-radium-223 and 72% post-placebo
- Compared with the ALSYMPCA ITT population, chemotherapy post-study drug patients were younger, had better ECOG PS, fewer metastases, and lower tALP and PSA




# Safety


- Maximum percentage decrease from baseline in hemoglobin and neutrophils was similar across treatment arms, but trended greater for platelets in radium-223 arm

## Maximum Percentage Decrease from Baseline


### Hemoglobin



### Neutrophils



### Platelets



# Safety

- Hematologic parameters were constant from last measurement pre-chemotherapy to 18 months post-chemotherapy in both treatment arms; no apparent impact of prior docetaxel
- Percentages of patients with hematologic values corresponding to grade 3 or 4 adverse events were generally low, trending higher among patients in the radium-223 than the placebo arm

Percentage of Patients in Chemotherapy Post-Study Drug Subgroup With Hematologic Laboratory Values Corresponding to Grade 3 or 4 Adverse Events

	Radium-223 N = 142		Placebo N = 64		P Value
	n	n (%)	n	n (%)	
Hemoglobin, < 8.0-6.5 g/dL or < 6.5 g/dL	116	9 (8)	49	2 (4)	0.509
Neutrophils, < 1-0.5 x 10 <sup>9</sup> /L or < 0.5 x 10 <sup>9</sup> /L	114	11 (10)	48	1 (2)	0.112
Platelets, < 50-25 x 10 <sup>9</sup> /L or < 25 x 10 <sup>9</sup> /L	116	7 (6)	49	1 (2)	0.438

# Overall Survival

- Similar proportions of radium-223 (41/142 [29%]) and placebo (21/64 [33%]) patients died during and within 30 days of completing chemotherapy
- Median OS from start of chemotherapy was 16.0 months post-radium-223 and 15.8 months post-placebo (HR = 1.23; 95% CI, 0.86-1.75)

# Conclusions

- Safety of chemotherapy post-radium-223 assessed in post hoc analysis showed no detrimental effects on hematology or OS
- Findings indicate that chemotherapy can be administered safely after radium-223